Search

Your search keyword '"Famulare, Christopher"' showing total 34 results

Search Constraints

Start Over You searched for: Author "Famulare, Christopher" Remove constraint Author: "Famulare, Christopher" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
34 results on '"Famulare, Christopher"'

Search Results

1. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

2. TP53 Y220C mutations in patients with myeloid malignancies.

4. Acute myeloid leukemia with mixed phenotype is characterized by stemness transcriptomic signatures and limited lineage plasticity

5. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

6. Data from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

7. Supplementary Table from LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms

8. Supplementary Table 1 from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

9. Supplementary Figures from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition

10. Supplementary Table 2 from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

11. Supplementary Figure from LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms

12. Supplementary Data from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

13. Data from LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms

14. Supplementary Methods from Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition

15. Supplementary Data from Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial

16. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification

17. Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia

18. Whole Genome Sequencing Comparison of Acute Myeloid Leukemia at Presentation and Remission Predicts Patient Outcome

19. Erythroid and Megakaryocytic Differentiation Program in JAK2-Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm

20. Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

21. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

22. Safety and efficacy of CPX-351 in younger patients (

23. Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

24. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.

25. Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

26. Deconvoluting Clonal and Cellular Architecture in IDH-Mutant Acute Myeloid Leukemia

31. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.

32. HMA/VEN treatment modifications and associated outcomes in <italic>IDH</italic>-mutant AML.

33. TP53Y220C Mutations in Patients with Myeloid Malignancies

34. Acute myeloid leukemia with mixed phenotype is characterized by stemness transcriptomic signatures and limited lineage plasticity.

Catalog

Books, media, physical & digital resources